These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16418691)

  • 1. Biomarkers: the link between therapeutic drug monitoring and pharmacodynamics.
    Oellerich M; Barten MJ; Armstrong VW
    Ther Drug Monit; 2006 Feb; 28(1):35-8. PubMed ID: 16418691
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacodynamic monitoring of immunosuppressive drugs.
    Yatscoff RW; Langman LJ; LeGatt DF
    Transplant Proc; 1996 Dec; 28(6):3013-5. PubMed ID: 8962169
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapeutic monitoring of immunosuppressive drugs: interest of calcineurin activity assessment in liver transplantation].
    Blanchet B
    Ann Pharm Fr; 2008 Mar; 66(2):96-101. PubMed ID: 18570908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic monitoring of calcineurin inhibitor therapy: is there a clinical benefit?
    Sommerer C; Giese T; Meuer S; Zeier M
    Nephrol Dial Transplant; 2009 Jan; 24(1):21-7. PubMed ID: 18842676
    [No Abstract]   [Full Text] [Related]  

  • 5. Relationship between calcineurin inhibition and plasma endothelin concentrations in cyclosporine-A-treated kidney transplant patients--a comment.
    Zehngawa W
    Eur J Clin Pharmacol; 2005 Jun; 61(4):317. PubMed ID: 15891875
    [No Abstract]   [Full Text] [Related]  

  • 6. Cryptococcus neoformans isolates from transplant recipients are not selected for resistance to calcineurin inhibitors by current immunosuppressive regimens.
    Blankenship JR; Singh N; Alexander BD; Heitman J
    J Clin Microbiol; 2005 Jan; 43(1):464-7. PubMed ID: 15635017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variation in leukocyte subset concentrations affects calcineurin activity measurement: implications for pharmacodynamic monitoring strategies.
    van Rossum HH; Romijn FP; Sellar KJ; Smit NP; van der Boog PJ; de Fijter JW; van Pelt J
    Clin Chem; 2008 Mar; 54(3):517-24. PubMed ID: 18218723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic monitoring of calcineurin inhibition therapy: principles, performance, and perspectives.
    van Rossum HH; de Fijter JW; van Pelt J
    Ther Drug Monit; 2010 Feb; 32(1):3-10. PubMed ID: 20009796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate mofetil monotherapy in liver transplantation.
    Stewart SF; Hudson M; Talbot D; Manas D; Day CP
    Lancet; 2001 Feb; 357(9256):609-10. PubMed ID: 11558493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of genetic polymorphism on disposition of calcineurin inhibitors in solid organ transplantation].
    Li D; Zhu L; Ye Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 35(9):1018-22. PubMed ID: 20871172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of calcineurin antagonists.
    Kapturczak MH; Meier-Kriesche HU; Kaplan B
    Transplant Proc; 2004 Mar; 36(2 Suppl):25S-32S. PubMed ID: 15041303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Optimal immunosuppressive therapy based on pharmacokinetics and pharmacodynamics of antimetabolites in clinical practice].
    Naito T
    Yakugaku Zasshi; 2010 Dec; 130(12):1695-700. PubMed ID: 21139397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATP-binding cassette transporters and calcineurin inhibitors: potential clinical implications.
    van Gelder T; Klupp J; Sawamoto T; Christians U; Morris RE
    Transplant Proc; 2001 May; 33(3):2420-1. PubMed ID: 11377580
    [No Abstract]   [Full Text] [Related]  

  • 15. New challenges and promises in solid organ transplantation pharmacogenetics: the genetic variability of proteins involved in the pharmacodynamics of immunosuppressive drugs.
    Pouché L; Stojanova J; Marquet P; Picard N
    Pharmacogenomics; 2016 Feb; 17(3):277-96. PubMed ID: 26799749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring calcineurin inhibitor therapy: localizing the moving target.
    Naesens M; Sarwal MM
    Transplantation; 2010 Jun; 89(11):1308-9. PubMed ID: 20458272
    [No Abstract]   [Full Text] [Related]  

  • 17. Relationship between calcineurin inhibition and plasma endothelin concentrations in cyclosporine-A-treated kidney transplant patients.
    Büchler M; Leibenguth P; Le Guellec C; Carayon A; Watier H; Odoul F; Autret-Leca E; Lebranchu Y; Paintaud G
    Eur J Clin Pharmacol; 2004 Dec; 60(10):703-8. PubMed ID: 15619133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct inhibitory effects of tacrolimus and cyclosporin a on calcineurin phosphatase activity.
    Fukudo M; Yano I; Masuda S; Okuda M; Inui K
    J Pharmacol Exp Ther; 2005 Feb; 312(2):816-25. PubMed ID: 15383634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcineurin inhibitors and cardiac hypertrophy.
    Force T; Rosenzweig A; Choukroun G; Hajjar R
    Lancet; 1999 Apr; 353(9161):1290-2. PubMed ID: 10218524
    [No Abstract]   [Full Text] [Related]  

  • 20. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications.
    Weimert NA; Derotte M; Alloway RR; Woodle ES; Vinks AA
    Ther Drug Monit; 2007 Apr; 29(2):141-9. PubMed ID: 17417067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.